AnaCardio raises €62.5 million Series B financing to advance transformational novel therapy in heart failure towards Phase 3 readiness

AnaCardio, a clinical-stage biopharmaceutical company, successfully raised €62.5 million in Series B financing co-led by Novo Holdings and the Ljungström family office. The funding will support Phase 2b development of AC01, a first-in-class oral ghrelin receptor agonist for advanced heart failure. AC01 demonstrated clinical proof of concept in Phase 1b/2a trials with a 22% increase in cardiac output and 4.8 percentage point improvement in ejection fraction, with favorable safety profile. The Phase 2b GOAL-HF2 study is expected to enroll first participants in Q4 2026, targeting Phase 3 readiness by 2028.